# AstraZeneca's shares fell 2% in morning trading.

*biotech · news · 2026-05-01 · CNBC*

## Key points

- The FDA advisory panel voted 6-3 against AstraZeneca's breast cancer drug camizestrant approval.
- Panel concerns focused on the SERENA-6 trial design, not camizestrant's toxicity or general safety.
- The SERENA-6 trial showed a 56% reduction in disease progression risk, but survival benefit was unclear.
- Panelists were unconvinced that early switching to camizestrant improves long-term survival versus current therapies.
- Camizestrant's limited impact means the negative vote is not material to AstraZeneca's long-term sales outlook.

**Companies:** AstraZeneca
**Countries:** United States, United Kingdom

[Read the full story on CNBC](https://www.cnbc.com/2026/05/01/astrazeneca-stock-az-fda-panel-cancer-drug.html)

---

Canonical: https://newsio.io/n/0f770d4f-c088-43b9-b8c6-e79563b2488d/astrazenecas-shares-fell-2-in-morning-trading-the-fda-generally-follows-the-reco
Summarized by Newsio from CNBC. https://newsio.io/how-it-works